Three-Component Subunit Vaccine Induces Protective Immunity Against Mycoplasma pneumoniae in Mice

Area of Science:

• Vaccinology
• Microbiology
• Immunology

Background:

• Mycoplasma pneumoniae (MP) is a significant cause of pediatric respiratory infections.
• Current lack of a licensed MP vaccine highlights the need for effective vaccine development.

Purpose of the Study:

• To develop a recombinant subunit vaccine candidate against Mycoplasma pneumoniae.
• To evaluate the protective efficacy of a novel three-component vaccine (MPtriV).

Main Methods:

• Developed a three-component vaccine using P1, P40/90, and a low-toxicity CARDS toxin mutant.
• Expressed and purified recombinant antigens in E. coli.
• Assessed immunogenicity and protective efficacy in a mouse model using Al(OH)3 and CpG adjuvants.

Main Results:

• Successfully produced high-purity recombinant proteins and selected an immunogenic, low-toxicity CARDS toxin mutant (E132A).
• The MPtriV vaccine elicited robust antigen-specific IgG antibody responses (approx. 10^4).
• Vaccination significantly reduced lung pathology and bacterial load, with Al(OH)3 + CpG adjuvant showing enhanced efficacy.

Conclusions:

• The MPtriV vaccine candidate, particularly with Al(OH)3 + CpG adjuvant, demonstrates significant immunogenicity, safety, and protective potential.
• This study provides a strong foundation for developing MP subunit vaccines.